[EMBO Reports] The authors propose that autoimmune outcomes are determined less by viral identity than by the immunological and anatomical context in which tolerance fails.

[Journal of Autoimmunity] Scientists analyzed the surface N-glycosylation pattern in Tregs from Myasthenia gravis (MG) patients. They demonstrated in vitro that the glycoreprogramming of Tregs, mimicking the glycan composition found in MG patients, leads to decreased suppression function.

[Gut] The authors investigated the role of growth differentiation factor 15 in regulating hepatocyte–neutrophil interactions and its impact on alcohol-associated liver disease progression.

[Science Advances] Researchers hypothesized that furan fatty acids are functional lipid mediators whose structural features, including antioxidant chemistry, β-oxidation susceptibility, and CoA conjugate stability, are primary determinants of hepatic metabolic activity.

[Diabetes] Scientists hypothesized that restoring α/β-hydrolase domain-containing protein 5 (ABHD5) supply to adipose tissue triglyceride lipase by either ABHD5 overexpression or interruption of the protein-protein interaction between ABHD5 and the mutant protein PNPLA3-I148M would recover lipolysis and ameliorate steatosis.

[British Journal of Cancer] The authors proposed a novel molecular mechanism of cabozantinib and provided insights into cabozantinib-based combination therapy for HCC using RNA-sequencing, a luciferase reporter assay, in vitro, and in vivo studies.

[Molecular Metabolism] Scientists hypothesized that regulation of AMPK and mTORC1 might underlie control of metabolic homeostasis by prohibitin-1 (PHB1) in the live, generating a constitutive hepatocyte specific PHB1 haploinsufficient mouse model to investigate these questions.

[Cellular Signalling] Investigators demonstrated that targeting enolase 1 with its specific inhibitor, ENOblock, markedly enhances the antitumor efficacy of sorafenib in HCC cells. Sorafenib, a multi-targeted kinase inhibitor that blocks intracellular kinases and receptor tyrosine kinases, has been established as the first-line treatment for advanced HCC.

[Oncology Reports] Researchers examined the effects of polybromo‑1 (PBRM1) knockdown on tumor‑related phenotypes and glucose metabolism in HCCC‑9810 intrahepatic cholangiocarcinoma cells, also evaluating the roles of aldolase, fructose‑bisphosphate A (ALDOA) and nuclear factor erythroid 2‑related factor 2 (NRF2).

[ACS Biomaterials Science & Engineering] The authors elucidate hepatic oxidative stress pathogenesis from a synergistic perspective, integrating indirect (inflammatory pathways) and direct (organelle stress, oxidase activation) reactive oxygen species generation routes, thereby filling gaps in existing literature.

[Ionis Pharmaceuticals, Inc.] Ionis Pharmaceuticals, Inc. partner GSK announced that the US FDA has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B virus (HBV) infection in combination with nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI) therapy in adult patients without cirrhosis, receiving NrtI therapy for at least six months, who have suppressed HBV DNA, and with HBV surface antigen levels ≤3000 IU/ml.

[Immutep Limited] Immutep Limited announced that the Australian Research Council (ARC) has awarded Monash University a grant of A$652,248 over three years under the ARC’s Linkage Projects scheme to support its continuing research collaboration with Immutep into Lymphocyte Activation Gene-3 (LAG-3).